John Stephen Babcook

USPTO Granted Patents = 25 (Patent Applications = 5)

CIPO Patents = 6 (Patent Applications = 6)

EPO Patents = 11 (Patent Applications = 15)

Average Co-Inventor Count = 4.7

ph-index = 7

Forward Citations = 352(Granted Patents)

Company Filing History:

6 out of 850

Millennium Pharmaceuticals Limited

Abbott Laboratories Corporation

patents

6. 2 out of 2

Amgen British Columbia Inc.

Var2 Pharmaceuticals Aps

10. 2 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12303544 - Cytotoxic and anti-mitotic compounds, and methods of using the same (2025-05-20),

2. 12053524 - Anti-podocalyxin antibodies and methods of using the same (2024-08-06),

3. 11617777 - Cytotoxic and anti-mitotic compounds, and methods of using the same (2023-04-04),

4. 11390673 - Anti-podocalyxin antibodies and methods of using the same (2022-07-19),

5. 11208497 - Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof (2021-12-28),

6. 11090383 - Anti-podocalyxin antibodies and methods of using the same (2021-08-17),

7. 10941211 - Anti-GCC antibody molecules and related compositions and methods (2021-03-09),

8. 10675355 - VAR2CSA-drug conjugates (2020-06-09),

9. 10517958 - Compositions and methods for the treatment of platinum-drug resistant cancer (2019-12-31),

10. 10201614 - Cytotoxic and anti-mitotic compounds, and methods of using the same (2019-02-12),

11. 9926378 - Antibodies that bind OV064 and methods of use therefor (2018-03-27),

12. 9522876 - Cytotoxic and anti-mitotic compounds, and methods of using the same (2016-12-20),

13. 9421277 - Antibodies that bind OV064 and methods of use therefor (2016-08-23),

14. 8785600 - Anti-GCC antibody molecules and related compositions and methods (2014-07-22),

15. 8779108 - Targeted binding agents against B7-H1 (2014-07-15),

Title: John Stephen Babcook: Innovator in Cancer Treatment Technologies

Introduction: John Stephen Babcook is a prominent inventor based in Vancouver, Canada, known for his significant contributions to the field of biomedical research. With a remarkable portfolio of 24 patents, Babcook has focused on developing innovative therapies for cancer treatment, showcasing his dedication to advancing medical science.

Latest Patents: Among his latest inventions are groundbreaking patents that have the potential to revolutionize cancer diagnostics and therapies. One notable patent is for "Anti-podocalyxin antibodies and methods of using the same," which encompasses anti-podocalyxin antibodies and their applications in the prevention, diagnosis, and treatment of cancer. Another significant patent, titled "Cytotoxic and anti-mitotic compounds, and methods of using the same," details compounds with cytotoxic and/or anti-mitotic activity. This patent also discusses methods for preparing and utilizing these compounds, creating pathways for developing effective pharmaceutical compositions.

Career Highlights: Over his career, John Stephen Babcook has collaborated with leading biotech companies. He has worked with Millennium Pharmaceuticals Limited, where he contributed to pioneering research on therapeutic agents. Additionally, he played a vital role at Zymeworks Inc., a company recognized for its innovative biotechnology solutions.

Collaborations: Throughout his professional journey, Babcook has teamed up with notable colleagues, including Jaspal Singh Kang and Bradley John Hedberg. These collaborations have facilitated the exchange of ideas and expertise, driving forward the development of impactful medical treatments.

Conclusion: John Stephen Babcook is a remarkable inventor whose work continues to influence the landscape of cancer treatment. With a substantial number of patents to his name and a commitment to innovative research, he embodies the spirit of invention in the biomedical field. His advancements not only hold promise for improved therapeutic options but also reflect the potential of collaborative efforts in scientific progress.

This text is generated by artificial intelligence and may not be accurate.